TerrAscend (OTCMKTS:TSNDF) & Biomerica (NASDAQ:BMRA) Head to Head Survey

TerrAscend (OTCMKTS:TSNDF) and Biomerica (NASDAQ:BMRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Risk and Volatility

TerrAscend has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Institutional & Insider Ownership

5.8% of TerrAscend shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 31.9% of TerrAscend shares are held by company insiders. Comparatively, 18.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares TerrAscend and Biomerica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TerrAscend	-31.01%	-32.93%	-5.49%
Biomerica	-84.79%	-97.19%	-61.57%

Earnings & Valuation

This table compares TerrAscend and Biomerica”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TerrAscend	$260.56 million	0.59	-$81.33 million	($0.11)	-4.50
Biomerica	$4.45 million	1.27	-$3.78 million	($1.27)	-1.44

Biomerica has lower revenue, but higher earnings than TerrAscend. TerrAscend is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for TerrAscend and Biomerica, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TerrAscend	0	1	0	0	2.00
Biomerica	1	0	0	0	1.00

Biomerica has a consensus price target of $9.00, indicating a potential upside of 391.80%. Given Biomerica’s higher probable upside, analysts plainly believe Biomerica is more favorable than TerrAscend.

Summary

TerrAscend beats Biomerica on 8 of the 13 factors compared between the two stocks.

About TerrAscend

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.